Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 6/20 | 0.82 |
| ▸ | DCTPP1 | Q9H773 | 5/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.61 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484352 | 0.90 | NR4A2 (1.00) | NR4A2DCTPP1TSHRNPC1RAB9A | |
| SCHEMBL11614993 | 0.89 | NR4A2 (0.82) | NR4A2DCTPP1TSHRNPC1RAB9A | |
| SCHEMBL11418944 | 0.89 | NPC1 (0.76) | NR4A2DCTPP1TSHRNPC1RAB9A | |
| SCHEMBL11617795 | 0.88 | NR4A2 (0.79) | NR4A2DCTPP1TSHRNPC1RAB9A | |
| SCHEMBL11617899 | 0.87 | NPC1 (0.63) | NR4A2DCTPP1TSHRNPC1RAB9A | |
| SCHEMBL11413840 | 0.84 | NPC1 (0.85) | NR4A2DCTPP1TSHRNPC1RAB9A | |
| SCHEMBL11406007 | 0.84 | NPC1 (0.85) | NR4A2DCTPP1TSHRNPC1RAB9A | |
| SCHEMBL11617747 | 0.84 | NPC1 (0.80) | NR4A2DCTPP1TSHRNPC1RAB9A | |
| SCHEMBL11617213 | 0.81 | NR4A2 (0.82) | NR4A2DCTPP1TSHRNPC1RAB9A | |
| SCHEMBL11406672 | 0.77 | NPC1 (0.80) | NR4A2DCTPP1TSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376079-B1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | VAN ANDEL RES INST (US) | 2016-08-10 | — | — | EP | claimed |
| US-8173670-B2 | Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids | VAN ANDEL RESEARCH INSTITUTE (US) | 2012-05-08 | — | — | US | claimed |
| EP-2376079-A1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | Van Andel Research Institute (US) | 2011-10-19 | — | — | EP | claimed |
| US-20110251211-A9 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-10-13 | — | — | US | claimed |
| WO-2010083218-A1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | VAN ANDEL RESEARCH INSTITUTE (US) | 2010-07-22 | — | — | WO | claimed |
| US-20100179167-A1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | VAN ANDEL RESEARCH INSTITUTE | 2010-07-15 | — | — | US | claimed |
| EP-2376079-B1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | VAN ANDEL RES INST (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2376079-B1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | VAN ANDEL RES INST (US) | 2016-08-10 | — | — | EP | disclosed |
| US-8173670-B2 | Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids | VAN ANDEL RESEARCH INSTITUTE (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173670-B2 | Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids | VAN ANDEL RESEARCH INSTITUTE (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173670-B2 | Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids | VAN ANDEL RESEARCH INSTITUTE (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2376079-A1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | Van Andel Research Institute (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110251211-A9 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-10-13 | — | — | US | disclosed |
| WO-2010083218-A1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | VAN ANDEL RESEARCH INSTITUTE (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010083218-A1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | VAN ANDEL RESEARCH INSTITUTE (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100179167-A1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | VAN ANDEL RESEARCH INSTITUTE | 2010-07-15 | — | — | US | disclosed |
| US-20100179167-A1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | VAN ANDEL RESEARCH INSTITUTE | 2010-07-15 | — | — | US | disclosed |
| US-20100179167-A1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | VAN ANDEL RESEARCH INSTITUTE | 2010-07-15 | — | — | US | disclosed |
| US-4086421-A | HYPOLIPIDEMIC AGENTS | SANDOZ, INC. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4049813-A | HYPOLIPIDEMIC AGENTS | SANDOZ, INC. (US) | 1977-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179167-A1 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | NR3C1, NR3C2, PDXK | NR4A2 67/4885DCTPP1 2528/4885TSHR 442/4885 |
| US-20110251211-A9 | METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS | NR3C1, NR3C2, PDXK | NR4A2 67/4885DCTPP1 2528/4885TSHR 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.